These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1200 related items for PubMed ID: 19739940

  • 21. Transferring type 2 diabetes patients with uncontrolled glycaemia from biphasic human insulin to biphasic insulin aspart 30: experiences from the PRESENT study.
    Shestakova M, Sharma SK, Almustafa M, Min KW, Ayad N, Azar ST, Danciulescu R, Khutsoane D, Guler S.
    Curr Med Res Opin; 2007 Dec; 23(12):3209-14. PubMed ID: 18005503
    [Abstract] [Full Text] [Related]

  • 22. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
    Hauner H, Kohlmann T, Landgraf W, Holle R, Pirk O, Scholten T.
    Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
    [Abstract] [Full Text] [Related]

  • 23. Safety and efficacy of inhaled insulin (AERx iDMS) compared with subcutaneous insulin therapy in patients with Type 1 diabetes: 1-year data from a randomized, parallel group trial.
    Moses RG, Bartley P, Lunt H, O'Brien RC, Donnelly T, Gall MA, Vesterager A, Wollmer P, Roberts A.
    Diabet Med; 2009 Mar; 26(3):260-7. PubMed ID: 19317821
    [Abstract] [Full Text] [Related]

  • 24. Biphasic insulin aspart given thrice daily is as efficacious as a basal-bolus insulin regimen with four daily injections: a randomised open-label parallel group four months comparison in patients with type 2 diabetes.
    Ligthelm RJ, Mouritzen U, Lynggaard H, Landin-Olsson M, Fox C, le Devehat C, Romero E, Liebl A.
    Exp Clin Endocrinol Diabetes; 2006 Oct; 114(9):511-9. PubMed ID: 17115349
    [Abstract] [Full Text] [Related]

  • 25. Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy.
    Yokoyama H, Tada J, Kamikawa F, Kanno S, Yokota Y, Kuramitsu M.
    Diabetes Res Clin Pract; 2006 Jul; 73(1):35-40. PubMed ID: 16513202
    [Abstract] [Full Text] [Related]

  • 26. The impact of insulin glargine on clinical and humanistic outcomes in patients uncontrolled on other insulin and oral agents: an office-based naturalistic study.
    Fischer JS, McLaughlin T, Loza L, Beauchamp R, Schwartz S, Kipnes M.
    Curr Med Res Opin; 2004 Nov; 20(11):1703-10. PubMed ID: 15537471
    [Abstract] [Full Text] [Related]

  • 27. Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE observational study.
    Valensi P, Benroubi M, Borzi V, Gumprecht J, Kawamori R, Shaban J, Shah S, Shestakova M, Wenying Y, IMPROVE Study Group Expert Panel.
    Int J Clin Pract; 2009 Mar; 63(3):522-31. PubMed ID: 19187170
    [Abstract] [Full Text] [Related]

  • 28. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen.
    Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J.
    Clin Ther; 2004 May; 26(5):724-36. PubMed ID: 15220016
    [Abstract] [Full Text] [Related]

  • 29. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study.
    Khutsoane D, Sharma SK, Almustafa M, Jang HC, Azar ST, Danciulescu R, Shestakova M, Ayad NM, Guler S, Bech OM, PRESENT Study Group.
    Diabetes Obes Metab; 2008 Mar; 10(3):212-22. PubMed ID: 18269636
    [Abstract] [Full Text] [Related]

  • 30. Insulin detemir under steady-state conditions: no accumulation and constant metabolic effect over time with twice daily administration in subjects with Type 1 diabetes.
    Bott S, Tusek C, Jacobsen LV, Endahl L, Draeger E, Kapitza C, Heise T.
    Diabet Med; 2006 May; 23(5):522-8. PubMed ID: 16681561
    [Abstract] [Full Text] [Related]

  • 31. Parental preference of prandial insulin aspart compared with preprandial human insulin in a basal-bolus scheme with NPH insulin in a 12-wk crossover study of preschool children with type 1 diabetes.
    Danne T, Råstam J, Odendahl R, Näke A, Schimmel U, Szczepanski R, Moeller J, Deiss D.
    Pediatr Diabetes; 2007 Oct; 8(5):278-85. PubMed ID: 17850471
    [Abstract] [Full Text] [Related]

  • 32. Fasting plasma glucose variability as a marker of nocturnal hypoglycemia in diabetes: evidence from the PREDICTIVE study.
    Niskanen L, Virkamäki A, Hansen JB, Saukkonen T.
    Diabetes Res Clin Pract; 2009 Nov; 86(2):e15-8. PubMed ID: 19747748
    [Abstract] [Full Text] [Related]

  • 33. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes.
    Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T.
    Diabetes Obes Metab; 2007 May; 9(3):290-9. PubMed ID: 17391154
    [Abstract] [Full Text] [Related]

  • 34. Injection of acidic or neutral insulin and pain: a single-center, prospective, controlled, noninterventional study in pediatric patients with type 1 diabetes mellitus.
    Karges B, Muche R, Riegger I, Moritz M, Heinze E, Debatin KM, Wabitsch M, Karges W.
    Clin Ther; 2006 Dec; 28(12):2094-101. PubMed ID: 17296465
    [Abstract] [Full Text] [Related]

  • 35. Insulin therapy in type 2 diabetes: role of the long-acting insulin glargine analogue.
    Yki-Järvinen H.
    Eur J Clin Invest; 2004 Jun; 34(6):410-6. PubMed ID: 15200492
    [Abstract] [Full Text] [Related]

  • 36. Metabolic control in patients with type 2 diabetes using Humalog Mix50 injected three times daily: crossover comparison with human insulin 30/70.
    Schernthaner G, Kopp HP, Ristic S, Muzyka B, Peter L, Mitteregger G.
    Horm Metab Res; 2004 Mar; 36(3):188-93. PubMed ID: 15057674
    [Abstract] [Full Text] [Related]

  • 37. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
    Hollander P, Cooper J, Bregnhøj J, Pedersen CB.
    Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
    [Abstract] [Full Text] [Related]

  • 38. Pre-meal insulin aspart compared with pre-meal soluble human insulin in type 1 diabetes.
    Home PD, Hallgren P, Usadel KH, Sane T, Faber J, Grill V, Friberg HH.
    Diabetes Res Clin Pract; 2006 Feb; 71(2):131-9. PubMed ID: 16054266
    [Abstract] [Full Text] [Related]

  • 39. Insulin glargine: a systematic review of a long-acting insulin analogue.
    Wang F, Carabino JM, Vergara CM.
    Clin Ther; 2003 Jun; 25(6):1541-77, discussion 1539-40. PubMed ID: 12860485
    [Abstract] [Full Text] [Related]

  • 40. Insulin glargine maintains equivalent glycemic control and better lipometabolic control than NPH insulin in type 1 diabetes patients who missed a meal.
    Rosak C, Jung R, Hofmann U.
    Horm Metab Res; 2008 Aug; 40(8):544-8. PubMed ID: 18493882
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 60.